Insulet (NASDAQ:PODD) had its target price raised by Barclays from $85.00 to $90.00 in a research note issued to investors on Thursday, MarketBeat reports. They currently have an overweight rating on the medical instruments supplier’s stock.
Several other research firms have also recently issued reports on PODD. Zacks Investment Research cut Insulet from a hold rating to a sell rating in a report on Tuesday, January 9th. BidaskClub raised Insulet from a sell rating to a hold rating in a report on Friday, January 26th. Raymond James Financial raised Insulet from a market perform rating to an outperform rating and set a $80.00 price target on the stock in a report on Monday, January 8th. UBS Group raised Insulet from a market perform rating to an outperform rating in a report on Monday, January 8th. Finally, Robert W. Baird upped their price target on Insulet from $65.00 to $72.00 and gave the company an outperform rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $69.31.
Insulet (NASDAQ PODD) opened at $80.46 on Thursday. The stock has a market capitalization of $4,523.52, a price-to-earnings ratio of -174.91 and a beta of 1.59. Insulet has a twelve month low of $38.43 and a twelve month high of $83.56. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.
Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). The company had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 39.74%. Insulet’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.16) EPS. equities research analysts forecast that Insulet will post -0.26 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in the business. California Public Employees Retirement System grew its holdings in shares of Insulet by 9.0% during the 2nd quarter. California Public Employees Retirement System now owns 65,700 shares of the medical instruments supplier’s stock valued at $3,371,000 after acquiring an additional 5,400 shares in the last quarter. State Street Corp grew its holdings in shares of Insulet by 7.7% during the 2nd quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock valued at $61,014,000 after acquiring an additional 85,280 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Insulet by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,746 shares of the medical instruments supplier’s stock valued at $2,296,000 after acquiring an additional 198 shares in the last quarter. Strs Ohio grew its holdings in shares of Insulet by 29.6% during the 3rd quarter. Strs Ohio now owns 7,000 shares of the medical instruments supplier’s stock valued at $385,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Insulet during the 3rd quarter valued at $435,000.
ILLEGAL ACTIVITY WARNING: “Insulet (PODD) PT Raised to $90.00” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://transcriptdaily.com/2018/02/23/insulet-podd-pt-raised-to-90-00.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.